New York, New York (PRWEB) February 12, 2014
Dialysis patients who allegedly suffered life-threatening heart events following administration of GranuFlo or NaturaLyte dialysis drugs continue to file GranuFlo lawsuits (http://www.thegranuflolawsuit.com/) in courts around the country, Bernstein Liebhard LLP reports. According to court documents, a New York woman filed suit against Fresenius Medical Care on January 31st for the alleged wrongful death of a relative from sudden cardiopulmonary arrest and a heart attack immediately following the administration of GranuFlo last February. The complaint, which was filed in Illinois St. Clair County Circuit Court, accuses Fresenius of failing to provide adequate warnings regarding GranuFlos association with an increased risk of heart attack and sudden cardiac death. (Case No. 14-L-134)
Since the GranuFlo recall, hundreds of dialysis patients and their families have filed lawsuits in courts around the country that echo the allegations put forth in this complaint. Our Firm expects that the number of GranuFlo lawsuit filings will continue to grow in the coming months, says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to dialysis patients who allegedly suffered cardiac arrest, heart attacks, stroke, sudden cardiac death or other serious heart events within 72 hours of the administration of GranuFlo or NaturaLyte.
The GranuFlo recall was announced in June 2012, following the release of an Urgent Product Notification by Fresenius Medical Care cautioning dialysis clinics about the potential association between inappropriate dosing of GranuFlo and NaturaLyte and the onset of serious cardiovascular events. The U.S. Food & Drug Administration (FDA) designated the notification a Class I recall, its most serious type of recall. A Class I recall indicates that use of a medical product could cause serious injury or death.
The New York Times also reported in June 2012 that the FDA had launched a probe of Fresenius Medical Cares handling of the GranuFlo recall, after becoming aware of a memo the company issued in November 2011 to its own clinics regarding the risks associated with GranuFlo and NaturaLyte. However, nothing was done at that time to notify thousands of dialysis centers outside the Fresenius network about the potential dangers associated with the products.*
According to court documents, more than 460 GranuFlo lawsuits have been in courts around the country since the announcement of the GranuFlo and NaturaLyte recall. The majority of these claims have been filed in a multidistrict litigation now underway in U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428) Additional lawsuits have been consolidated at the state level in Massachusetts Middlesex County Superior Court. (In re Consolidated Fresenius Cases, No. MICV2013-03400-O)
Individuals who allegedly suffered serious heart events following the administration of GranuFlo or NaturaLyte may be entitled to compensation from Fresenius Medical Care. Find out more about filing a GranuFlo lawsuit at Bernstein Liebhard LLPs website, or the Firms Facebook page: https://www.facebook.com/granuflolawsuit. For more information, and to arrange for a free case review, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016